

PERSONAL INFORMATION

Aaron Emmanuel Sosa Mejia

WORK EXPERIENCE

- February 2018- Present **Senior Medical Officer**
Danish Medicines Agency (Denmark)
Regulatory affairs, clinical assessor of trials in Oncology, monthly participation at CHMP meeting.
- March 2022- Present **Alternate CHMP Member for Denmark**
European Medicines Agency (Netherlands)
(Co)Rapporteur for the Haematology & Oncology medicinal products portfolio.
Monthly participation at CHMP.
- February 2021-March 2022 **Member of the Scientific Advice Working Party (SAWP)**
European Medicines Agency (Netherlands)
Monthly participation at SAWP meeting.
- February 2016-January 2018 **Attending Physician, Medical Oncology**
Instituto Oncologico Rosell - Hospital Sagrat Cor (Spain)
Direct care of cancer patients.
- June 2015-January 2016 **Attending Physician, Medical Oncology**
Hospital Platon (Spain)
Direct care of cancer patients.
- June 2015-December 2017 **Consultant and Case Manager**
Advance Medical (Spain)
Write clinical reports for second medical opinions.

EDUCATION AND TRAINING

- May 2010-May 2015 **Specialist in Medical Oncology**
Ministro de Educacion, Cultura y Deporte (Spain)
Medical Oncology
- January 2006-December 2009 **Specialist in Internal Medicine**
Universidad de San Carlos de Guatemala (Guatemala)
- January 1998-June 2004 **Doctor of Medicine**
Universidad de San Carlos de Guatemala (Guatemala)

ADDITIONAL INFORMATION

Expertise Medical Oncology
Immunotherapy
Lung Cancer
Head & Neck Cancer
Breast Cancer
Colon Cancer
Gastroesophageal Cancer
Urogenital Cancer

Publications Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study.

Buxo E, Sosa A, Reig O, Victoria I, Caballero M, Grau JJ, Garcia-Morillo M.
Ann Otol Rhinol Laryngol. 2018 Jul;127(7):456-462. doi: 10.1177/0003489418778066.
Clinical assessment of immune-related adverse events.
Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R.
Ther Adv Med Oncol. 2018 Mar 30;10:1758835918764628. doi: 10.1177/1758835918764628.
eCollection 2018.
Possible application of circulating free tumor DNA in non-small cell lung cancer patients.
Karachaliou N, Sosa AE, Molina MA, Centelles Ruiz M, Rosell R.
J Thorac Dis. 2017 Oct;9(Suppl 13):S1364-S1372. doi: 10.21037/jtd.2017.09.59. Review.
PMID: 29184675
The combination of checkpoint immunotherapy and targeted therapy in cancer.
Karachaliou N, Gonzalez-Cao M, Sosa A, Berenguer J, Bracht JWP, Ito M, Rosell R.
Ann Transl Med. 2017 Oct;5(19):388. doi: 10.21037/atm.2017.06.47. Review.
PMID: 29114546
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to
guide treatment decisions.
Mayo-de-Las-Casas C, Jordana-Ariza N, Garzon-Ibanez M, Balada-Bel A, Bertran-Alamillo J,
Viteri-Ramirez S, Reguart N, Munoz-Quintana MA, Lianes-Barragan P, Camps C, Jantus E,
Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Vinolas N, Santos-Rodriguez AK, Majem M,
Garcia-Pelaez B, Villatoro S, Perez-Rosado A, Monasterio JC, Ovalle E, Catalan MJ, Campos R,
Morales-Espinosa D, Martinez-Bueno A, Gonzalez-Cao M, Gonzalez X, Moya-Horno I, Sosa AE,
Karachaliou N, Rosell R, Molina-Vila MA.
Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288.
PMID: 28911086
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung
cancer.
Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote
A, Altavilla G, Rosell R.
Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. doi: 10.1080/13543784.2017.1324572. Epub
2017 May 18. Review.
PMID: 28463570
Pharmacological management of relapsed/refractory NSCLC with chemical drugs.
Karachaliou N, Sosa AE, Barron FB, Gonzalez Cao M, Santarpia M, Rosell R.
Expert Opin Pharmacother. 2017 Feb;18(3):295-304. doi: 10.1080/14656566.2017.1285284. Epub
2017 Jan 29. Review.
PMID: 28103738
HER3 as a Therapeutic Target in Cancer.
Karachaliou N, Lazzari C, Verlicchi A, Sosa AE, Rosell R.
BioDrugs. 2017 Feb;31(1):63-73. doi: 10.1007/s40259-016-0205-2. Review.
PMID: 28000159
Annual or biennial lung cancer CT screening?
Karachaliou N, Sosa AE, Rosell R.
J Thorac Dis. 2016 Sep;8(9):2424-2426. No abstract available.
PMID: 27746993
Unraveling the genomic complexity of small cell lung cancer.
Karachaliou N, Sosa AE, Rosell R.
Transl Lung Cancer Res. 2016 Aug;5(4):363-6. doi: 10.21037/tlcr.2016.07.02. No abstract available.
PMID: 27650513
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
Garcia-Albeniz X, Gallego R, Hofheinz RD, Fernandez-Esparrach G, Ayuso-Colella JR, Bombi JA,
Conill C, Cuatrecasas M, Delgado S, Gines A, Miquel R, Pages M, Pineda E, Pereira V, Sosa A,
Reig O, Victoria I, Feliz L, Maria de Lacy A, Castells A, Burkholder I, Hochhaus A, Maurel J.
World J Gastroenterol. 2014 Nov 14;20(42):15820-9. doi: 10.3748/wjg.v20.i42.15820.

PMID: 25400468

Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy.

Sosa AE, Grau JJ, Feliz L, Pereira V, Alcaraz D, Munoz-Garcia C, Caballero M.

Eur Arch Otorhinolaryngol. 2014 Feb;271(2):373-8. doi: 10.1007/s00405-013-2537-6. Epub 2013 May 4.

PMID: 23644939

Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone.

Caballero M1, E Sosa A, Tagliapietra A, Grau JJ.

Head Neck. 2013 Feb;35(2):E52-4. doi: 10.1002/hed.21870. Epub 2011 Dec 5.

PMID: 22144378

Projects No grants held or application/ownership of patents.

Memberships Past member of ASCO, ESMO and SEOM (Spanish Society of Medical Oncology).

Other Relevant Information